Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, Antonia SJ, Gray JE, Eschrich SA, Chen DT, Cress WD, Haura EB, Beg AA. Schabath MB, et al. Among authors: antonia sj. Oncogene. 2016 Jun 16;35(24):3209-16. doi: 10.1038/onc.2015.375. Epub 2015 Oct 19. Oncogene. 2016. PMID: 26477306 Free PMC article.
Gene therapy for lung cancer.
Antonia SJ, Sotomayor E. Antonia SJ, et al. Curr Opin Oncol. 2000 Mar;12(2):138-42. doi: 10.1097/00001622-200003000-00007. Curr Opin Oncol. 2000. PMID: 10750725 Review.
Gene therapy for lung cancer. An introduction.
Haura EB, Sotomayor E, Antonia SJ. Haura EB, et al. Among authors: antonia sj. Methods Mol Med. 2003;75:529-43. doi: 10.1385/1-59259-324-0:529. Methods Mol Med. 2003. PMID: 12407762 Review.
Gene therapy for lung cancer.
Haura EB, Sotomayor E, Antonia SJ. Haura EB, et al. Among authors: antonia sj. Mol Biotechnol. 2003 Oct;25(2):139-48. doi: 10.1385/MB:25:2:139. Mol Biotechnol. 2003. PMID: 14526124 Review.
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Chiappori AA, et al. Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508. Clin Cancer Res. 2008. PMID: 18316570 Clinical Trial.
210 results